Anticipating & Understanding Results
Anticipating the Results of the Phase III AIDS Vaccine Trial in Thailand
September 2009
AVAC's recent report, Anticipating the Results of the Phase III AIDS Vaccine Trial in Thailand, was designed to help advocates prepare in advance for the initial announcement. The report is available in English and Thai. AVAC will be providing an updated and expanded version of this report that includes the trial data.
Anticipating the Results of PrEP Trials: A powerful new HIV prevention tool may be on the horizon. Are we prepared?
August 2008
This report
provides background on pre-exposure prophylaxis
(PrEP) research, the status of current clinical
trials, and issues concerning effective
delivery should PrEP prove effective. It closes
with a list of priority issues that need
attention now from governments, global health
institutions, donors, researchers, and
advocates. This report is also available in Spanish.
A New Way to Protect Against
HIV? Understanding the Results of Male
Circumcision Studies for HIV Prevention
September 2007
This
document is designed to help prevention
advocates understand the ramifications of
findings from studies of male circumcision for
HIV prevention, and to explore the
opportunities and challenges associated with
implementation.
Female-Initiated HIV Prevention: What will we learn from upcoming trials?
July 2007
This document is designed to help HIV prevention advocates understand the implications of findings from two studies of female-initiated HIV prevention methods. These large-scale efficacy trials are the first of this kind to be brought through scheduled completion.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir "PrEP" trials
March 2005
Research is currently taking place that could change the way we think about preventing HIV infection. Tenofovir, a drug that is now widely used in treatment of HIV and AIDS, is being tested in Africa, Asia, and the Americas for possible use as a product that HIV-negative people could take regularly to reduce their risk of HIV infection. This potential application of tenofovir is called pre-exposure prophylaxis or "PrEP." No drug has yet been licensed for PrEP. Legitimate ethical concerns raised by some advocates have led to cancellations and delays in some of the PrEP trials. On March 24, AVAC released a report, "Will a Pill a Day Prevent HIV? Anticipating the Results of the Tenofovir "PrEP" Trials," that examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Understanding the Results of the AIDSVAX Trial
May 2003
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX. The brochure is also available in French and Spanish.